Trial · NCT03222492
Results by group204
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 204
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.6 mg/kg Brentuximab Vedotin | 0.333 | 95% Confidence Interval 0.043 to 0.777 | Proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.6 mg/kg Placebo | 0.000 | 95% Confidence Interval 0.000 to 0.842 | Proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 1.2 mg/kg Brentuximab Vedotin | 0.571 | 95% Confidence Interval 0.184 to 0.901 | Proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 1.2 mg/kg Placebo | 0.000 | 95% Confidence Interval 0.000 to 0.842 | Proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | Brentuximab Vedotin in Pooled Participants | 0.462 | 95% Confidence Interval 0.192 to 0.749 | Proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | Placebo in Pooled Participants | 0.000 | 95% Confidence Interval 0.000 to 0.602 | Proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.6 mg/kg Brentuximab Vedotin | 0.400 | 95% Confidence Interval 0.053 to 0.853 | proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 0.6 mg/kg Placebo | 0.000 | 95% Confidence Interval 0.000 to 0.842 | proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 1.2 mg/kg Brentuximab Vedotin | 0.667 | 95% Confidence Interval 0.094 to 0.992 | proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | 1.2 mg/kg Placebo | 0.000 | 95% Confidence Interval 0.000 to 0.842 | proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | Brentuximab Vedotin in Pooled Participants | 0.500 | 95% Confidence Interval 0.157 to 0.843 | proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. | Placebo in Pooled Participants | 0.000 | 95% Confidence Interval 0.000 to 0.602 | proportion of participants | |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | 0.6 mg/kg Brentuximab Vedotin | Week 12 | 0.167 | 95% Confidence Interval 0.004 to 0.641 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | 0.6 mg/kg Placebo | Week 12 | 0.000 | 95% Confidence Interval 0.000 to 0.842 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | 1.2 mg/kg Brentuximab Vedotin | Week 12 | 0.143 | 95% Confidence Interval 0.004 to 0.579 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | 1.2 mg/kg Placebo | Week 12 | 0.000 | 95% Confidence Interval 0.000 to 0.842 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Brentuximab Vedotin in Pooled Participants | Week 12 | 0.154 | 95% Confidence Interval 0.019 to 0.454 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | Placebo in Pooled Participants | Week 12 | 0.000 | 95% Confidence Interval 0.000 to 0.602 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | 0.6 mg/kg Brentuximab Vedotin | Week 24 | 0.333 | 95% Confidence Interval 0.043 to 0.777 | proportion of participants |
| Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36. | 0.6 mg/kg Placebo | Week 24 | 0.000 | 95% Confidence Interval 0.000 to 0.842 | proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03222492/results